

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): January 5, 2021

TONIX PHARMACEUTICALS HOLDING CORP.  
(Exact name of registrant as specified in its charter)

Nevada  
(State or Other Jurisdiction  
of Incorporation)

001-36019  
(Commission  
File Number)

26-1434750  
(IRS Employer  
Identification No.)

26 Main Street, Suite 101, Chatham, New Jersey 07928  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (212) 980-9155

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TNXP	The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On January 5, 2021, Tonix Pharmaceuticals Holding Corp (the "Company") issued a press release announcing the signing of a second research collaboration agreement with Massachusetts General Hospital, a teaching hospital of Harvard Medical School, to develop its TNX-1500 product candidate, a humanized monoclonal antibody (mAb) that targets the CD40-ligand (also known as CD154, T-BAM or 5c8 antigen1) for the prevention and treatment of organ transplant rejection. A copy of the press release is furnished as Exhibit 99.01 hereto and incorporated herein by reference.

The Company updated its investor presentation, which is used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. A copy of the presentation is filed as Exhibit 99.02 hereto and incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.01 and 99.02 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 8.01. Other Events.**

On January 5, 2021, the Company announced the signing of a second research collaboration agreement with Massachusetts General Hospital to develop its TNX-1500 product candidate for the prevention and treatment of organ transplant rejection. The new collaboration will focus on kidney transplantation, while an earlier collaboration with MGH is focused on heart transplantation.

Transplantation experts led by Tatsuo Kawai, M.D., Ph.D., Surgical Director of the Living Donor Transplantation and Dialysis Access Program at MGH and Professor of Surgery at Harvard Medical School will study TNX-1500 in kidney transplantation in a variety of models including non-human primates. The goal of the collaboration is to advance TNX-1500 as a potential first-in-class therapeutic to prevent and treat kidney transplant rejection.

*Forward-Looking Statements*

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

---

**Item 9.01 Financial Statements and Exhibits.**

(d)	<b>Exhibit No.</b>	<b>Description.</b>
	99.01	<a href="#">Press Release of the Company, dated January 5, 2021</a>
	99.02	<a href="#">Corporate Presentation by the Company for January 2021</a>

---

**SIGNATURE**

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**TONIX PHARMACEUTICALS HOLDING CORP.**

Date: January 5, 2021

By: /s/ Bradley Saenger  
Bradley Saenger  
Chief Financial Officer

---

## **Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix's Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection**

### **Expands Ongoing Research Collaboration Between Tonix and MGH Studying TNX-1500 in Heart Transplantation**

#### **TNX-1500 May Hold Potential in Treating Autoimmune Diseases Including Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis**

CHATHAM, N.J., January 5, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the signing of a second research collaboration agreement with Massachusetts General Hospital (MGH), a teaching hospital of Harvard Medical School, to develop TNX-1500, a humanized monoclonal antibody (mAb) that targets the CD40-ligand (also known as CD154, T-BAM or 5c8 antigen<sup>1</sup>) for the prevention and treatment of organ transplant rejection. Transplant organ rejection occurs when the immune system of the organ recipient attacks the new organ as if it was an infection or tumor. The new collaboration will focus on kidney transplantation, while an earlier collaboration with MGH is focused on heart transplantation.

Transplantation experts led by Tatsuo Kawai, M.D., Ph.D., Surgical Director of the Living Donor Transplantation and Dialysis Access Program at MGH and Professor of Surgery at Harvard Medical School (HMS) will study TNX-1500 in kidney transplantation in a variety of models including non-human primates. The goal of the collaboration is to advance TNX-1500 as a potential first-in-class therapeutic to prevent and treat kidney transplant rejection.

Dr. Kawai said, "Anti-CD40-ligand therapy has a unique activity in controlling the immune response to organ transplants.<sup>2</sup> There remains a significant need for new treatments to reduce the toxicity of current treatments by more selectively suppressing immune responses or inducing specific tolerance to the transplanted organ. Anti-CD40-ligand has shown promise not only to effectively suppress rejection but also to facilitate 'transplant tolerance' in multiple preclinical transplant models.<sup>6</sup>"

The study of TNX-1500 in heart transplantation at MGH began last year under the direction of Richard N. Pierson III, M.D., scientific director of the Center for Transplantation Sciences in the Department of Surgery at MGH and Professor of Surgery HMS.

#### **Key Advances in Anti-CD40-Ligand Antibody Engineering Led to TNX-1500**

Tonix's President and Chief Executive Officer, Seth Lederman, M.D. said, "A substantial body of evidence in humans and animals indicates that mAbs targeting CD40-ligand have the potential to be an important therapeutic option for preventing or treating transplant organ rejection and as a treatment for autoimmune disorders. Despite the recognized promise of anti-CD40-ligand therapy, first generation anti-CD40- ligand mAbs were limited because their constant fragment (Fc) domain interacted with a receptor called FcγRII, which raised concerns over an increased risk of thrombosis. Second generation anti-CD40- ligand mAbs had dramatically reduced binding to FcγRII, but had other issues, including decreased efficacy<sup>5-7</sup>. TNX-1500 is a third generation anti-CD40- ligand mAb that has been designed by protein engineering to target CD40-ligand therapeutically, while potentially decreasing FcγRII binding and the potential for thrombosis."

<sup>1</sup> Lederman, S. & al. *J. Exp. Med.* 175:1091-1101 (1992)

<sup>2</sup> Kawai T, et al. *Am J Transplant.* 4(9):1391 (2004)

<sup>3</sup> O'Neill NA, et al. *Transplantation.* 101(9): 2038 (2017)

<sup>4</sup> Zhang T, et al. *Immunotherapy.* 7(8):899 (2015)

<sup>5</sup> Waters J, *BioCentury*; October 26, (2018)

<sup>6</sup> NCT02273960; *ClinicalTrials.gov*; "Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)"; results posted April 1, 2019, accessed July 29, 2019)

<sup>7</sup> Ferrant JL et al., *International Immunol.* (11):1583 (2004)

#### **About CD40-Ligand**

CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. CD40-ligand is also known as CD154, the T cell-B cell activating molecule (T-BAM), TRAP or gp39. CD40-ligand is a member of the Tumor Necrosis Factor (TNF) Super Family. Other TNF Super Family members have proven to be targets for antagonist mAbs. Licensed mAbs against TNFα include: infliximab (Remicade®), adalimumab (Humira®), certolizumab pegol (Cimzia®), and golimumab (Simponi®) for the treatment of certain autoimmune conditions. Also, etanercept (Enbrel®) is a TNFα antagonist receptor fusion protein. A licensed mAb against RANKL (CD254) is denosumab (Prolia® or Xgeva®) for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.

Remicade® and Simponi® are trademarks of Janssen; Humira® is a trademark of AbbVie Inc.; Cimzia® is a trademark of UCB S. A.; Enbrel®, Prolia® and Xgeva® are trademarks of Amgen Inc.

#### **Tonix Pharmaceuticals Holding Corp.**

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL\*, is in mid-Phase 3 development for the management of fibromyalgia since positive data on the RELIEF Phase 3 trial were recently reported. The Company expects topline data in the Phase 3 RALLY study in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix's lead vaccine candidate, TNX-1800\*\*, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-801\*\*, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.

\*TNX-102 SL is an investigational new drug and has not been approved for any indication.

\*\*TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication.

This press release and further information about Tonix can be found at [www.tonixpharma.com](http://www.tonixpharma.com).

### **Forward Looking Statements**

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (the “SEC”) on March 24, 2020, and periodic reports filed with the SEC on or after the date thereof. All Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

### **Contacts**

Jessica Morris (corporate)  
Tonix Pharmaceuticals  
[investor.relations@tonixpharma.com](mailto:investor.relations@tonixpharma.com)  
(862) 904-8182

Olipriya Das, Ph.D. (media)  
Russo Partners  
[Olipriya.Das@russopartnersllc.com](mailto:Olipriya.Das@russopartnersllc.com)  
(646) 942-5588

Peter Vozzo (investors)  
Westwicke  
[peter.vozzo@westwicke.com](mailto:peter.vozzo@westwicke.com)  
(443) 213-0505

---





# Investor Presentation

NASDAQ:TNXP

1



January 2021

Version P0267 1-5-2021 (Doc 0756)

© 2021 Tonix Pharmaceuticals Holding Corp.



## Cautionary Note on Forward-Looking Statements

2

Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain U.S. Food and Drug Administration clearances or approvals and noncompliance with its regulations; our need for additional financing; delays and uncertainties caused by the global COVID-19 pandemic; substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. The forward-looking statements in this presentation are made as of the date of this presentation, even if subsequently made available by Tonix on its website or otherwise. Tonix does not undertake an obligation to update or revise any forward-looking statement, except as required by law. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (the "SEC") on March 24, 2020, and periodic reports and current reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

© 2021 Tonix Pharmaceuticals Holding Corp.



## Tonix Pharmaceuticals

3

### Clinical-stage biopharmaceutical company

- Committed to discovering and developing innovative and proprietary new therapeutics

### Focus on developing biologics and small molecules

- **Central Nervous System (CNS)**
  - Lead: fibromyalgia program in mid-Phase 3
  - Pipeline: Pain, neurology, psychiatry, addiction
- **Immunology**
  - Lead: COVID-19 vaccine in non-human primate testing
  - Pipeline: Vaccines, organ transplantation, oncology, autoimmune diseases

© 2021 Tonix Pharmaceuticals Holding Corp.

## Our Pipeline – CNS Portfolio

4

	CANDIDATES	INDICATION	STATUS
CNS Portfolio	TNX-102 SL <sup>1</sup>	<b>Fibromyalgia (FM) - Lead Program</b>	<b>Mid-Phase 3 – ongoing</b>
		PTSD Sleep Disturbance <sup>2</sup>	Phase 3 ready
		Agitation in Alzheimer's	Phase 2 ready
		Alcohol Use Disorder	Phase 2 ready
	TNX-1300 <sup>3</sup>	Cocaine Intoxication / Overdose	Phase 2
	TNX-1900 <sup>4</sup>	Migraine and craniofacial pain	Clinical – pre-IND <sup>5</sup>
TNX-601 CR	Depression, PTSD, Neurocognitive Dysfunction from Corticosteroids	Clinical – pre-IND <sup>6</sup>	
TNX-1600 <sup>7</sup>	Depression, PTSD and ADHD	Preclinical	

<sup>1</sup>TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.

<sup>2</sup>PTSD Sleep Disturbance is a proposed new indication pending discussion with FDA

<sup>3</sup>TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution) is an investigational new biologic and has not been approved for any indication; licensed from Columbia University.

<sup>4</sup>Acquired from Trigemina; license agreement with Stanford University

<sup>5</sup>A Phase 2 trial under an investigator-initiated IND has been completed in the U.S. using TNX-1900

<sup>6</sup>TNX-601 CR is in the pre-IND stage in the U.S.; a Phase 1 trial for formulation development was recently completed outside of the U.S.

<sup>7</sup>Acquired from TRImaran Pharma; license agreement with Wayne State University

© 2021 Tonix Pharmaceuticals Holding Corp.

## Our Pipeline – Immunology & Biodefense Portfolio

5

	CANDIDATES	INDICATION	STATUS
Immunology Portfolio	<b>TNX-1800</b>	<b>Covid-19 vaccine – Prioritized Program<sup>1</sup></b>	<b>Preclinical</b>
	TNX-1810, TNX-1820, TNX-1830	Covid-19 vaccine <sup>1</sup>	Preclinical
	TNX-2300	Covid-19 vaccine <sup>2</sup>	Preclinical
	TNX-2600	Covid-19 vaccine <sup>2</sup>	Preclinical
	TNX-801	Smallpox and monkeypox preventing vaccine <sup>3</sup>	Preclinical
	TNX-1200	Smallpox and monkeypox preventing vaccine <sup>4</sup>	Preclinical
	TNX-1500	Organ Transplant Rejection/Autoimmune Conditions <sup>5</sup>	Preclinical
	TNX-1700	Gastric and pancreatic cancers <sup>6</sup>	Preclinical
	TNX-701	Radioprotection	Preclinical

<sup>1</sup>Live attenuated vaccine based on horsepox virus vector

<sup>2</sup>Live attenuated vaccine based on bovine parainfluenza virus vector; option for license with Kansas State University

<sup>3</sup>Live attenuated vaccine based on horsepox virus

<sup>4</sup>Live vaccine based on vaccinia virus

<sup>5</sup>anti-CD40L humanized monoclonal antibody

<sup>6</sup>recombinant trefoil factor 2 (TFF2) based protein; licensed from Columbia University

© 2021 Tonix Pharmaceuticals Holding Corp.

## Overview of TNX-102 SL\*

6

**Protectic® proprietary formulation of cyclobenzaprine that supports sublingual administration**

**TNX-102 SL is a non-opioid, centrally-acting analgesic that works by improving sleep quality**

### ◇ Scientific Rationale for Protectic® Formulation ◇

- Engenders unique pharmacokinetic and pharmacodynamic properties that emphasize sleep properties of cyclobenzaprine while minimizing undesirable properties
- Potential therapeutic value in a constellation of disorders where sleep disturbances are:
  - Co-morbid
  - Involved in the onset, progression and severity of the disease

\*TNX-102 SL is in clinical stage of development and not approved for any indication

© 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-102 SL: Differentiation from Oral Formulations

7

FEATURE	BENEFIT	ADVANTAGE
Cyclobenzaprine	40+ years as oral medication	Established safety record
Formulation: Protectic®	Allows submucosal absorption	Not achievable with oral formulation
Administration: sublingual	Bypasses gut	Avoids first-pass metabolism; reduced formation of "activating" metabolite
Pharmacokinetic profile	Rapid absorption (peak at ~4 hours, low trough levels 8-24 hours)	Desired profile for nighttime action
Dose: low (2.8 to 5.6 mg)	Recruitment of high affinity receptors (5-HT <sub>2A/1</sub> , α <sub>1</sub> , H <sub>1</sub> )	Complimentary trimodal mechanism of action with less risk of off-target interference

© 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-102 SL: Potential Treatment for Fibromyalgia (FM)

8



Volkswagen Check Engine (Photograph). (2011, October 14). Wikipedia

- Fibromyalgia is considered a central nervous system disorder with symptoms that include: chronic widespread pain, nonrestorative sleep, fatigue, diminished cognition and mood disturbances
- Believed to result from inappropriate pain signaling in central nervous system in the absence of peripheral injury<sup>1</sup>
- An estimated 6-12 million adults in the U.S. have fibromyalgia<sup>2</sup>, 90% of whom are women
- Causes significant impairment in all areas of life<sup>3</sup>
  - Lower levels of health-related quality of life – reduced daily functioning
  - Interference with work (loss of productivity, disability)
- Fewer than half of those treated for fibromyalgia receive complete relief from the three FDA-approved drugs<sup>4</sup>
- Substantial off-label use of narcotic painkillers and prescription sleep aids<sup>5</sup>
  - Among those diagnosed, more than one-third have used prescription opioids as a means of treatment<sup>6</sup>

<sup>1</sup> Phillips K & Clauw D]. Best Pract Res Clin Rheumatol 2011;25:141.

<sup>2</sup> American Chronic Pain Association (www.theacpa.org, 2019)

<sup>3</sup> Schaefer et al., Pain Pract, 2015.

<sup>4</sup> The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica); Duloxetine (Cymbalta); Milnacipran (Savella)

<sup>5</sup> Patient Trends: Fibromyalgia, Decision Resources, 2011.

<sup>6</sup> Berger A, Duke E, Meiri S, Edsberg J, Oster G. Int J Clin Pract. 2007; 61(8):1499-1500.

© 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-102 SL 5.6 mg: Results from Completed Positive Phase 3 RELIEF Study

9

### Completed Positive Trial in FM:

- Topline results announced in December 2020
- 503 participants randomized across 39 sites in U.S.
- 95% of participants were women

### Topline Efficacy Results:

- Achieved statistical significance in the pre-specified primary efficacy endpoint of reducing daily pain (p=0.01)
- Activity shown in key secondary endpoints measuring improvements in sleep and fatigue

### Safety:

- Well tolerated; side effects consistent with known side effects of cyclobenzaprine; no new safety signals observed

© 2021 Tonix Pharmaceuticals Holding Corp.



## No Recognized Abuse Potential in Clinical Studies

10

### Active ingredient is cyclobenzaprine, which is structurally related to tricyclic antidepressants

- Cyclobenzaprine interacts with receptors that regulate sleep quality: 5-HT<sub>2A</sub>, α<sub>1</sub>-adrenergic, histaminergic H<sub>1</sub>, and muscarinic M<sub>1</sub> receptors
- Cyclobenzaprine does not interact with the same receptors as traditional hypnotic sleep drugs, benzodiazepines or non-benzodiazepines that are associated with retrograde amnesia
- Cyclobenzaprine-containing product was approved 40 years ago and current labeling (May 2016) indicates no abuse or dependence concern

### TNX-102 SL NDA can be filed without drug abuse and dependency assessment studies\*

\*April 2017 meeting minutes from the March 2017 FDA meeting

© 2021 Tonix Pharmaceuticals Holding Corp.



## Positive Phase 3 F304/RELIEF Study: Design

11

### General study characteristics:

- Randomized, double-blind, placebo-controlled study in fibromyalgia in 39 U.S. sites (full sample size N=503)
- Adaptive Design: one unblinded interim analysis based on 50% of randomized participants

#### TNX-102 SL once-daily at bedtime

5.6 mg (2 x 2.8 mg tablets)<sup>1</sup>

N= 248

#### Placebo once-daily at bedtime

N= 255

14 weeks

<sup>1</sup>Two week run in at 2.8 mg dose at bedtime, followed by 12 weeks at 5.6 mg dose

© 2021 Tonix Pharmaceuticals Holding Corp.

### Primary endpoint (Week 14):

- Daily diary pain severity score change (TNX-102 SL 5.6 mg vs. placebo) from baseline in the weekly average as measured by the numerical rating scale (NRS), using mixed model repeated measures analysis with multiple imputation (MMRM with MI)

### Key Secondary endpoints (Week 14):

- Patient Global Impression of Change responder analysis
- Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptom Domain score
- FIQ-R Function Domain score
- PROMIS Sleep Disturbance instrument T-score
- PROMIS Fatigue instrument T-score
- Weekly average of the daily diary assessment of sleep quality

### Pivotal efficacy study to support NDA approval



## F304/RELIEF Study Topline Data: Statistical Significance Achieved on Pre-specified Primary Efficacy Endpoint (p=0.01)

12

Primary Outcome Measure at Week 14	Placebo (N=255)	TNX-102 SL <sup>2</sup> (N=248)	Treatment Difference	P value
	LS Mean Change from Baseline (SE)	LS Mean Change from Baseline (SE)	Difference in LS Mean Change from Baseline Between TNX-102 SL and Placebo (SE)	
Daily Pain Diary, NRS	-1.5 (0.12)	-1.9 (0.12)	-0.4 (0.16)	<b>0.010*</b>

Statistical Method: Mixed Model Repeated Measures analysis with Multiple Imputation

\*p<0.0452 (requisite p-value hurdle for full study after Interim Analysis)

<sup>1</sup> Same primary endpoint analysis for FDA approvals of Cymbalta® and Lyrica® in fibromyalgia  
Abbreviations: LS = least squares; NRS = numeric rating scale; SE = standard error

- Primary efficacy analysis also supported by an exploratory 30% responder analysis of daily diary pain, which indicated 46.8% on TNX-102 SL versus 34.9% on placebo achieved a 30 percent or greater reduction in pain (logistic regression; odds ratio [95% CI]: 1.67 [1.16, 2.40]; p=0.006)
  - 30% responder analysis was the primary analysis in F301 AFFIRM study of TNX-102 SL 2.8 mg
  - Also was the same primary endpoint analysis for FDA approval of Savella® for fibromyalgia


<sup>2</sup> TNX-102 SL is in clinical stage of development and not approved for any indication

© 2021 Tonix Pharmaceuticals Holding Corp.



## F304/RELIEF Study: Primary Efficacy Endpoint Results (continued)

13



## F304/RELIEF Study: Key Secondary Efficacy Endpoints

14

Outcome Measure at Week 14	Intent-to-Treat Analysis <sup>1</sup>	P-value
<b>Non-Specific</b>		
Patient Global Impression of Change	Responder Analysis: Proportion "Much Improved" or "Very Much Improved"	0.058
<b>Fibromyalgia Syndrome-Related</b>		
FIQ-R Symptom Domain	Mean Change from Baseline	0.007 <sup>‡</sup>
FIQ-R Function Domain	Mean Change from Baseline	0.009 <sup>‡</sup>
PROMIS Fatigue	Mean Change from Baseline	0.018 <sup>‡</sup>
Daily Sleep Quality Diary, NRS	Mean Change from Baseline	<0.001 <sup>‡</sup>
PROMIS Sleep Disturbance	Mean Change from Baseline	<0.001 <sup>‡</sup>

<sup>‡</sup> nominally significant at p<0.0452

<sup>1</sup> Combined periods (pre- and post-interim analysis); responder analysis is by Logistic Regression (missing = non-responder); the five mean change analyses are by Mixed Model Repeated Measures with Multiple Imputation

Abbreviations: FIQ-R = Fibromyalgia Impact Questionnaire - Revised; NRS = numeric rating scale; PROMIS = Patient-Reported Outcomes Measurement Information System


\*TNX-102 SL is in clinical stage of development and not approved for any indication

© 2021 Tonix Pharmaceuticals Holding Corp.

## F304/RELIEF Study: Continuous Responder Analysis (CRA) Graph

15

- The CRA graph allows one to see the proportion of responders over an entire range of cut-off points
- For example,  $\geq 30\%$  improvement in pain is considered clinically meaningful in pain studies
- Looking at that vertical line at  $\geq 30\%$  and visualizing a horizontal line to the y-axis tells you the proportion of each arm that achieved that level of pain improvement or better (47% for TNX-102 SL and 35% for placebo)
- It can be seen that TNX-102 SL separates from placebo, always at a higher proportion, up to about  $\geq 95\%$  improvement



© 2021 Tonix Pharmaceuticals Holding Corp.



## Adverse Events\* (AEs) in F304/RELIEF Study

16

	TNX-102 SL (N=248)		Placebo (N=255)		Total (N=503)	
	N	%	N	%	N	%
<b>Administration Site Reactions</b>						
Tongue/mouth numbness	43	17.3	2	0.8	45	8.9
Tongue/mouth pain/discomfort	29	11.7	5	2.0	34	6.8
Taste impairment	16	6.5	1	0.4	17	3.4
Tongue/mouth tingling	14	5.6	1	0.4	15	3.0
<b>Systemic Adverse Events</b>						
Somnolence/Sedation	14	5.6	3	1.2	17	3.4

\* Table reports only AEs at rate of greater than 5% in either treatment arm

### No serious and unexpected AEs in RELIEF related to TNX-102 SL

- Systemic AEs comparable with prior studies and consistent with approved oral cyclobenzaprine product labeling
- Oral AEs similar to prior studies with TNX-102 SL, although tongue/mouth numbness at about half the rate in RELIEF

© 2021 Tonix Pharmaceuticals Holding Corp.



## Safety and Tolerability in F304/RELIEF Study

17

- No new safety signals in RELIEF at TNX-102 SL 5.6 mg dose
- 82.3% in active arm and 83.5% in placebo arm completed the study
- 8.9% in active arm and 3.9% in placebo arm discontinued due to adverse events
- 7 SAEs in study: 2 in active arm and 5 in placebo arm
  - Of 2 in active arm, one was motor vehicle accident with multiple bone fractures, and other was pneumonia due to infection; both deemed unrelated to TNX-102 SL
- Similar oral administration site reactions as in prior studies with TNX-102 SL
- Overall low rates of systemic side effects, highest being somnolence/sedation at 5.6% in active group, 1.2% in placebo

© 2021 Tonix Pharmaceuticals Holding Corp.



## TNX-102 SL 5.6 mg for Fibromyalgia: 2<sup>nd</sup> Phase 3 F306/RALLY Study – Enrollment Ongoing

18

### General study characteristics:

- Randomized, double-blind, placebo-controlled study in fibromyalgia in approximately 40 U.S. sites (N=670)
- Adaptive Design: one unblinded interim analysis based on 50% of randomized participants<sup>1</sup>

#### TNX-102 SL once-daily at bedtime

5.6 mg (2 x 2.8 mg tablets)<sup>2</sup> N= ~335<sup>3</sup>

#### Placebo once-daily at bedtime

N= ~335<sup>3</sup>

14 weeks

### Primary endpoint (Week 14):

- Daily diary pain severity score change (TNX-102 SL 5.6 mg vs. placebo) from baseline in the weekly average as measured by the numerical rating scale (NRS), using mixed model repeated measures analysis with multiple imputation (MMRM with MI)

### Key Secondary endpoints (Week 14) include<sup>4</sup>:

- Daily diary sleep quality NRS score change
- Fibromyalgia Impact Questionnaire – Revised (FIQR): Symptoms Domain change
- PROMIS Fatigue instrument change

### Interim results expected in 2<sup>nd</sup> quarter 2021

### Topline results expected in 4<sup>th</sup> quarter 2021

### Potential pivotal efficacy study to support NDA approval

<sup>1</sup>Pending submission and agreement from FDA on statistical analysis plan  
<sup>2</sup>Two week run in at 2.8 mg dose at bedtime, followed by 12 weeks at 5.6 mg dose  
<sup>3</sup>Pending submission and agreement from FDA on protocol amendment  
<sup>4</sup>PROMIS = Patient-Reported Outcomes Measurement Information System

## Approved Fibromyalgia Pharmacotherapies

19

### Pfizer

- Drug: Lyrica® or pregabalin (U.S. patent expired in 2018)
- Approved: 2004
- Mechanism: modulates nerve impulses involved in the transmission of pain through selective binding to the alpha2-delta protein of the voltage-gated calcium channels in CNS tissues
- Peak Sales: Approximately \$5 billion (including all approved indications)

### Lilly

- Drug: Cymbalta® or duloxetine (U.S. patent expired 2014)
- Approved: 2004
- Mechanism: serotonin and norepinephrine reuptake inhibitor (SNRI)
- Peak Sales: Approximately \$5 billion (including all approved indications)

### Abbvie (developed by Forest Laboratories)

- Drug: Savella® or milnacipran (on patent)
- Approved: 2009
- Mechanism: serotonin and norepinephrine reuptake inhibitor (SNRI)
- Peak Sales: Approximately \$130 million (approved for fibromyalgia indication only)

© 2021 Tonix Pharmaceuticals Holding Corp.

## Other Fibromyalgia Pharmacotherapies in Development in the U.S.

20

### Axsome Therapeutics - AXS-14

- Drug: esreboxetine
- Mechanism: Selective norepinephrine reuptake inhibitor
- Developmental Stage: At least mid-Phase 3 (Phase 2 and Phase 3 trial positive\*)

### Aptinyx - NYX-2925

- Drug: ((2S, 3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-diazaspiro(3.4)octan-2-yl)butanamide)
- Mechanism: NMDA receptor modulator
- Developmental Stage: Phase 2 study is "active, not recruiting"

### Teva - Ajovy®

- Drug: fremanezumab
- Anti-CGRP antibody
- Developmental Stage: Phase 2 proof-of-concept study "recruiting"

\*licensed from Pfizer, Jan 2020

© 2021 Tonix Pharmaceuticals Holding Corp.

## Overview of Posttraumatic Stress Disorder (PTSD)

21

**PTSD is a chronic disabling disorder in response to experiencing traumatic event(s)**

**Symptoms of PTSD fall into four clusters:**

1. Intrusion (aversive memories, nightmares, flashbacks)
2. Avoidance (avoiding persons, places or situations)
3. Mood/cognitions (memory block, emotional numbing, detachment from others)
4. Hyperarousal (anxiety, agitation & sleep disturbance)

**Impact of PTSD:**

- Impaired daily function and substantial interference with work and social interactions
- Reckless or destructive behavior
- Increased health care utilization and greater medical morbidity

**PTSD is a risk factor for:**

- Depression, alcohol and substance abuse, absenteeism/ unemployment, homelessness, violent acts, suicidal thoughts and suicide

© 2021 Tonix Pharmaceuticals Holding Corp.

## PTSD: Prevalence and Demographics

22

### PTSD is a chronic response to traumatic event(s)

- A majority of people will experience a traumatic event at some point in their lifetime<sup>1</sup>
  - 20% of women and 8% of men in the U.S. who experience significant trauma develop PTSD<sup>1</sup>

### Adult Civilians:

- **Lifetime prevalence:** 6.1% (14.4 million adults in the U.S.)<sup>2</sup>
  - Persistent → 1/3 fail to recover, even after several years following the trauma<sup>2</sup>

- **Twelve month prevalence:** U.S. 4.7% (12 million adults)<sup>2</sup>  
EU 2.3% (~10.0 million adults)<sup>3</sup>

- Vast majority of PTSD is civilian PTSD
- Among diagnosed civilians with PTSD, the population tends to be about 2/3 female<sup>4</sup>
  - Women more likely to develop than men<sup>2</sup> :

<sup>1</sup>Kessler et al., Arch Gen Psychiatry 1995; 52:1048

<sup>2</sup>Goldstein et al., 2016 (adjusted for 2019)

<sup>3</sup>The European Union Market Potential for a New PTSD Drug. Prepared for Tonix Pharmaceuticals by Proceta Consultants Ltd, September 2016

<sup>4</sup>IMS Consulting, Market Sizing & Treatment Dynamics: "Post-Traumatic Stress Disorder (PTSD) Patients", 2016

© 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-102 SL: Hypothesized Novel Mechanism Targets Sleep Quality for Recovery from PTSD

23

### PTSD is a disorder of recovery

- Most people exposed to extreme trauma recover over a few weeks
- In PTSD, recovery process impeded due to insufficient sleep-dependent memory processing<sup>1,2</sup>

### Memory processing is essential to recovery

- Ongoing vulnerability to memory intrusions and trauma triggers if there is deficient consolidation of new learning (extinction)

### TNX-102 SL targets sleep quality<sup>3</sup>

- The active ingredient in TNX-102 SL, cyclobenzaprine, interacts with receptors that regulate sleep quality: strongly binds and potently blocks 5-HT<sub>2A</sub>,  $\alpha_1$ -adrenergic, histamine H<sub>1</sub>, and muscarinic M<sub>1</sub> receptors, permissive to sleep-dependent recovery processes

<sup>1</sup>Straus LD, Acheson DT, Risbrough VB, Drummond SPA. Sleep Deprivation Disrupts Recall of Conditioned Fear Extinction. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017; 2(2):123-129. <sup>2</sup>Murkar ALA, De Koninck J. Consolidative mechanisms of emotional processing in REM sleep and PTSD. Sleep Med Rev. 2018; 41:173-184.

<sup>3</sup>Daugherty et al., Abstract 728, Society of Biological Psychiatry 70th Annual Scientific Convention, May 14-16, 2015, Toronto Ontario, Canada

© 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-102 SL for PTSD: Completed Phase 3 P302/RECOVERY, Study Design

24

### General study characteristics:

- Randomized, double-blind, placebo-controlled study with baseline CAPS-5<sup>1</sup>  $\geq 33$  in approximately 29 U.S. sites
- Enrollment restricted to study participants with PTSD who experienced an index trauma  $\leq 9$  years from the date of screening
- Both civilian and military-related PTSD included (N=192)

**TNX-102 SL once-daily at bedtime**  
5.6 mg (2 x 2.8 mg tablets) N= 99

**Placebo once-daily at bedtime**  
N= 93

12 weeks

### Primary endpoint:

- CAPS-5<sup>1</sup> mean change from baseline at Week 12 (TNX-102 SL 5.6 mg vs. placebo)

### Secondary endpoints include:

- Change from baseline Clinical Global Impression – Severity scale
- Change from baseline Sheehan Disability Scale total score
- PROMIS Sleep Disturbance Instrument T-score change from baseline
- Patient Global Impression of Change

**Interim analysis:** results reported in 1Q 2020 which resulted in stop for futility recommendation; enrollment was stopped and currently-enrolled participants who were already enrolled completed the study

**Topline data:** reported 4Q2020, statistical significance not achieved for primary endpoint; activity observed in secondary endpoints

<sup>1</sup>CAPS-5 = Clinician-Administered PTSD Scale for DSM-5

© 2021 Tonix Pharmaceuticals Holding Corp.



## P302/RECOVERY Topline Results Trial Efficacy Endpoints

25

Week 12 Outcome Measure	TNX-102 SL (N=80)		Placebo (N=83)		TNX-102 SL v. Placebo				
	LS Mean	SE	LS Mean	SE	LSMD	SE	95% CI	p-value*	ES
CAPS-5 CFB – Primary Endpoint	-20.7	1.97	-18.5	1.9	-2.2	2.3	-6.7, 2.3	0.343	0.15
CGI-S score CFB	-2	0.18	-1.5	0.17	-0.5	0.22	-0.9, -0.1	0.024	0.36
PGIC score	2.3	0.16	2.8	0.16	-0.5	0.19	-0.9, -0.1	0.007	0.43
PROMIS SD T-score CFB	-13	1.57	-9.4	1.51	-3.5	1.82	-7.1, 0.1	0.055	0.30
CAPS-5 item E6/SD CFB	-1.3	0.19	-0.9	0.19	-0.4	0.23	-0.8, 0.1	0.086	0.28

Abbreviations: CAPS-5 = Clinician-Administered PTSD Scale; CFB = change from baseline; CGI-S = Clinical Global Impression – Severity; CI = confidence interval; ES = effect size; LS = least squares; LSMD = least squares mean difference; N = number; PGIC = Patient Global Impression of Change; PROMIS = Patient-Reported Outcomes Measurement Information System; SD = sleep disturbance; SE = standard error  
\*All secondary p-values are descriptive

© 2021 Tonix Pharmaceuticals Holding Corp.

## P302/RECOVERY Topline Results Safety Endpoints

26

### Change in Weight, Blood Pressure, Heart Rate between Baseline and Last Assessment

Change in Outcome Measure	TNX-102 SL (N=80)		Placebo (N=84)	
	Mean	95% CI	Mean	95% CI
Weight (kg)	0.03	-0.48, 0.54	0.58	-0.01, 1.16
Systolic blood pressure (mmHg)	1.8	-0.8, 4.5	1.3	-1.4, 4.0
Diastolic blood pressure (mmHg)	1.5	-0.5, 3.5	-0.2	-2.3, 1.9
Heart rate (beats per minute)	1.8	-1.0, 4.5	1.5	-1.1, 4.0

Abbreviations: CI = confidence interval; N = number

- Greater weight increase in placebo by 0.58 kg than TNX-102 SL by 0.03 kg
- No clinically meaningful increases in systolic or diastolic blood pressure by TNX-102 SL
- No clinically meaningful increase in heart rate by TNX-102 SL

© 2021 Tonix Pharmaceuticals Holding Corp.

## P302/RECOVERY Topline Results Effects of TNX-102 SL on Female Sexual Function

27

Wk 12 Outcome Measure	TNX-102 SL (N=65)		Placebo (N=64)		TNX-102 SL v. Placebo				
	LS Mean	SE	LS Mean	SE	LSMD	SE	95% CI	p-value**	ES
CSFQ-14 CFB* (female)	4.6	0.84	2.4	0.86	2.2	1.21	-0.2, 4.6	0.07	0.32

Abbreviations: CSFQ-14 = Changes in Sexual Functioning Questionnaire short form; CI = confidence interval; ES = effect size; LS = least squares; LSMD = least squares mean difference; N = number; SE = standard error; Wk = week.

\*higher score on CSFQ-14 indicates better sexual functioning

\*\* p-value is descriptive

- Trend for improvement in female sexual function in TNX-102 SL group after 12 weeks of treatment – underpowered sample size but effect size of 0.32
  - Of importance given impairment in sexual function common with SSRIs
- Too few male subjects in TNX-102 SL group (N=15) and placebo group (N=19) for meaningful statistical comparison

© 2021 Tonix Pharmaceuticals Holding Corp.

# TNX-102 SL for Posttraumatic Stress Disorder (PTSD): Three Recent Trials

28

## Phase 3 P302 "RECOVERY" – Civilian PTSD (79% female)<sup>1</sup>

- **Reported Topline in December 2020 (mITT, N = 163)**
- 2 groups: Placebo (n = 83) and TNX 5.6 mg (n = 80)
- Primary endpoint (5.6 mg dose): CAPS-5 CFB, Week 12: MMRM,  $P=0.34$  (two-sided)
- Secondary endpoints (5.6 mg dose): CGI-S\* ( $P=0.024$ ) and **PGIC\* ( $P=0.007$ )**
- Stopped enrollment in Feb 2020 (randomized, N=192) when interim analysis recommended stop for "futility"

## Phase 3 P301 "HONOR" – Military-related PTSD (89% male)<sup>2</sup>

- **Discontinued August 2018 (randomized, N=358) due to "futility" at interim analysis (IA)**
- 2 groups at IA: Placebo (n = 125) and TNX 5.6 mg (n = 127)
- Primary endpoint (5.6 mg dose): CAPS-5 CFB, Week 12: MMRM with MI,  $P=0.60$  (two-sided)
- Secondary endpoints (5.6 mg dose): **PGIC\* ( $P=0.020$ )** and CGI-I ( $P=0.34$ )\*\*

## Phase 2 P201 "AtEase" – Military-related PTSD (93% male)<sup>3</sup>

- **Reported Topline in May 2016 (mITT, N=231)**
- 3 groups: Placebo (n = 92), TNX 2.8 mg (n = 90) and TNX 5.6 mg (n=49)
- Primary endpoint (2.8 mg dose): CAPS-5 CFB, Week 12: MMRM,  $P=0.26$  (two-sided)
- Secondary endpoints (5.6 mg dose): CAPS-5 ( $P=0.053$ ), **PGIC\* ( $P=0.035$ )** and CGI-I ( $P=0.041$ )\*\*

<sup>1</sup>ClinicalTrials.gov Identifier: NCT03841773

<sup>2</sup>ClinicalTrials.gov Identifier: NCT03062540

<sup>3</sup>ClinicalTrials.gov Identifier: NCT02277704

Abbreviations: CAPS-5 = Clinician-Administered PTSD Scale for DSM-5; CFB = change from baseline; CGI-S = Clinician Global Impression - Severity; CGI-I = Clinician Global Impression - Improvement; PGIC = Patient Global Impression of Change; mITT = modified Intent-to-Treat; MMRM = mixed model repeated measures; MI = multiple imputation; \*continuous variable analysis; \*\*responder analysis

© 2021 Tonix Pharmaceuticals Holding Corp.

# Adverse Event Profile of TNX-102 SL 5.6 mg in Phase 3 Trials in Both Civilian (P302) and Military-Related (P301) PTSD

29

- No serious and unexpected AEs in PTSD at the 5.6 mg dose
- No systemic AE at  $\geq 5\%$  observed for 5.6 mg dose that was common to both studies
- Incidence of oral hypoesthesia (numbness) and oral paraesthesia (tingling) similar in both studies

Systemic Adverse Event* #		P301 (Military)		P302 (Civilian)	
		Placebo (N=134)	5.6 mg (N=134)	Placebo (N=91)	5.6 mg (N=96)
Systemic Adverse Event* #	Somnolence	9.0%	15.7%		
	Dry Mouth			3.3%	8.3%
	URTI			4.4%	5.2%
Local Administration Site Reaction* #	Hypoesthesia oral	1.5%	37.3%	1.1%	29.2%
	Paraesthesia oral	0.7%	9.7%	1.1%	7.3%
	Tongue discomfort			0.0%	5.2%
	Product Taste Abnormal	3.0%	11.9%		

URTI = upper respiratory tract infection

\*Only adverse events (AEs) are listed that are at a rate of  $\geq 5\%$  in the TNX-102 SL-treated groups

\*No values in a row for either study means the AE in the active group in that study was at a rate of  $<5\%$

© 2021 Tonix Pharmaceuticals Holding Corp.

# Common Observations from Three Recent PTSD Trials Testing TNX-102 SL

30

- **Consistent nominal improvement or trend at Week 12 for sleep measurements**
  - Supported by nominal benefits in PROMIS Sleep Disturbance and E6 sleep disturbance item in CAPS-5 analysis
  - Evidence of "target engagement", appropriate pharmacokinetics for nighttime dosing
- **Consistent nominal improvement or trend at Week 12 for Patient Global Impression of Change (PGIC) and Clinician Global Impression (CGI-I and CGI-S)**
  - For PGIC, participants themselves rate how they feel; for CGI, clinicians rate the overall improvement; neither measurement is tied to any theoretical construct of disease recovery such as the assumptions inherent in the CAPS-5 items
  - High placebo responses not seen in global patient- and clinician-reported measures (i.e., PGIC, CGI)
- **High placebo response measured by CAPS-5 change from baseline**
  - Studies appear to have provided "enhanced" standard of care
- **Consistent drug separation from placebo on CAPS-5 at Week 4<sup>1</sup> not sustained at Week 12**
  - Continued trend of improvement in placebo groups throughout courses of studies
- **Low systemic side effects and good tolerability across the three trials**

<sup>1</sup>In P201, 2.8 mg dose showed effect size at Week 4 of 0.38; in P301, 5.6 mg effect size at Week 4 of 0.30; in P302, 5.6 mg effect size at Week 4 of 0.29

© 2021 Tonix Pharmaceuticals Holding Corp.

## Sleep Disturbance Recognized as Clinically Valid Approach to Address PTSD

31

### VA Study on Sleep in PTSD currently recruiting non-registrational 4-arm study of trazodone, eszopiclone, gabapentin and placebo on VA PTSD patients<sup>1</sup>

- **Insomnia Severity Index (ISI) is the primary endpoint**
- The PTSD subscale of the Pittsburgh Sleep Quality Index (PSQI) is a secondary endpoint
- CAPS-5 administered by centralized raters is a secondary endpoint
- Targeting 1,334 patients

### Trazodone has a similar proposed Mechanism of Action to TNX-102 SL<sup>1</sup>

- Both are antagonists of 5-HT<sub>2A</sub>
- Both are taken at bedtime<sup>2</sup>

<sup>1</sup>ClinicalTrials.gov Identifier: NCT03668041

<sup>2</sup>Bedtime use of trazodone is experimental and off-label, approved dosing for depression is *three times daily*

© 2021 Tonix Pharmaceuticals Holding Corp.

## Future Plans: TNX-102 SL for PTSD

32

### Plan to propose new indication: "treatment of sleep disturbance associated with PTSD"

- Sleep disturbance is a core symptom of PTSD
- TNX-102 SL works by improving sleep quality which, as a result, improves sleep-dependent emotional memory processing necessary to recovery from PTSD; demonstrated by activity in secondary endpoints measuring sleep disturbance across three registration quality trials (~800 randomized participants) that correlated with patient rated global improvement on PGIC
- New indication would require acceptance by FDA

### Phase 3 Study of Kenyan Police

- Placebo response in CNS studies is growing faster in the U.S. than in other countries<sup>1,2</sup>
- Protocol in development with Moi University – expected start date 3Q 2021

### Pharmacogenomics on study participants

- P302 had high percentage of participant DNA collected; P301 has a subset of participant DNA available
- Exome sequencing to focus on: drug metabolizing enzymes; neurotransmitter receptors and transporters; genes related to sleep quality ratings; genes related to fear extinction memory processing as evidenced by reduction in trauma-reminder triggered psychological or physical reactions; genes related to response on PGIC

<sup>1</sup>Gopalakrishnan, M et al. J Clin Psychiatry. 2020; 81(2):19r12960

<sup>2</sup>Laughren, TP J Clin Psychiatry. 2020; 81(2):19com13110 © 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-102 SL Intellectual Property – U.S. Protection expected until 2035

33

### Composition of matter (eutectic): Protection expected to 2034/2035

- United States Patent and Trademark Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188 in May 2018, Patent No. 10117936 in November 2018, Patent No. 10,357,465 in July 2019, and Patent No. 10,736,859 in August 2020
- European Patent Office (EPO) issued European Patent No. 2968992 in December 2019 (validated in 37 countries). Opposition filed in October 2020 by Hexal AG
- China National Intellectual Property Administration issued Chinese Patent No. ZL 201480024011.1 in April 2019
- Japanese Patent Office (JPO) issued Japanese Patent No. 6310542 in March 2018, Patent No. 6614724 in November 2019, and Patent No. 6717902 in June 2020
- 10 granted patents (Indonesia, Saudi Arabia, New Zealand, Australia, Mexico, Taiwan, Israel, South Africa)
- 31 patent applications pending (4 being allowed in U.S., China, Israel, South Africa)

### Composition of matter (sublingual): Protection expected to 2033

- NZIPO issued New Zealand Patent No. 631144 in March 2017 and Patent No. 726488 in January 2019
- Taiwanese Intellectual Property Office issued Taiwanese Patent No. 1590820 in July 2017, Patent No. 1642429 in December 2018 and Patent No. 1683660 in February 2020
- Australian Patent Office issued Australian Patent No. 2013274003 in October 2018 and Patent No. 2018241128 in September 2020
- JPO issued Japanese Patent No. 6259452 in December 2017
- 20 patent applications pending

### Method of use (PTSD) for cyclobenzaprine: Protection expected to 2030

- Hong Kong Patent Office issued Hong Kong Patent No. HK1176235 in September 2018
- USPTO issued U.S. Patent No. 9918948 in March 2018
- European Patent Office (EPO) issued European Patent No. 2501234B1 in September 2017 (validated in 37 countries). In response to an opposition filed in June 2018, EPO's Opposition Division maintained the patent in unamended form in October 2019. Opponent has appealed
- 1 patent application pending

© 2021 Tonix Pharmaceuticals Holding Corp.

## Opportunities to Expand TNX-102 SL to Other Indications

34

### Role of sleep disturbance more established in common psychiatric and neurological/pain disorders

- Recognized as a core symptom of many of these disorders
- Traditional sleep medications, which increase sleep quantity, may not provide benefit (benzodiazepines in major depression) or are contraindicated

#### Psychiatric Disorders

- Stress Disorders (PTSD)
- Mood Disorders (Depression)
- Anxiety Disorders
- Addiction (Alcohol Use Disorder)

#### Psychiatric Symptoms of Neurological Disorders

- Agitation in Alzheimer's
- Psychosis in Parkinson's, Alzheimer's and other dementias

#### Chronic Pain States

- Chronic wide-spread pain (fibromyalgia)
- Osteoarthritis

### Growing recognition that there are many disorders where sleep disturbances may have a role in the pathophysiology (cardiovascular, metabolic, neurologic)

- Sleep quality plays a homeostatic role *in several disorders*

© 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-1800<sup>1</sup>: a COVID-19 Vaccine Candidate

35

- **Utilizes Tonix's proprietary horsepox virus as a vector**
  - Encodes a protein from SARS-CoV-2, the cause of COVID-19
  - Developed in collaboration with University of Alberta, Canada
- **Animal testing with Southern Research Institute**
  - Non-human primate immune response positive results reported in 4Q20
  - Non-human primate CoV-2 challenge testing data expected in 1Q21
- **Manufacturing agreement with FUJIFILM Diosynth**
  - Development for Good Manufacturing Practice (GMP) manufacturing for human trials
  - GMP<sup>2</sup> clinical supply expected to be ready for human trials in 2021<sup>3</sup>

<sup>1</sup>TNX-1800 (horsepox/CoV-2 spike live vaccine) is at the pre-IND stage of development

<sup>2</sup>Good Manufacturing Practice = GMP

<sup>3</sup>We cannot predict whether the global COVID-19 pandemic will impact the timing of these milestones

© 2021 Tonix Pharmaceuticals Holding Corp.

## Concerns With Current COVID-19 Vaccines with Emergency Use Authorization (EUA)

36

- **Durability of protection**
  - Are vaccinated people protected one year later?
  - Durable protection is associated with T cell response
- **Protection against death/ventilator support**
  - Protection against mild/moderate disease is not a strong motivation for many to be vaccinated
- **Does vaccination protect against forward transmission**
  - Highly contagious nature of CoV-2 is a major problem driving pandemic
- **Safety of vaccine**
  - Risk:benefit for different age groups may vary – e.g. adults below 30 have low risk of disease
- **No biomarker of protection**
  - No test to establish protection from vaccination
- **Cost and accessibility of vaccines**
  - High production cost and issues with cold-chain process distribution

© 2021 Tonix Pharmaceuticals Holding Corp.



## Warp-Speed COVID-19 Vaccines: Live Virus Vaccines Take Longer to Develop

37

- **mRNA**
  - Moderna (mRNA-1273, LNP<sup>1</sup>-encapsulated CoV-2 Spike ["Spike"] mRNA) EUA<sup>2</sup>
  - Pfizer & BioNTech (LNP-encapsulated Spike mRNA) EUA
- **Subunit**
  - Sanofi/GSK (recombinant Spike protein with adjuvant<sup>3</sup>) In Phase 3
  - Novavax (NVX-CoV2373, recombinant Spike protein with adjuvant<sup>4</sup>) In Phase 3
- **Non-replicating virus**
  - J&J (Ad26.COVS-2, Ad26 encoding Spike) In Phase 3
  - Astra-Zeneca/Oxford (AZD1222, ChAdOx-1 encoding Spike) In Phase 3 (EUA in UK and India)
- **Live attenuated virus**
  - Merck (TMV-083, modified measles<sup>5</sup>-encoding Spike) Phase 1
  - Merck (V591, pseudo-typed VSV<sup>6</sup>-encoding Spike) Phase 1

<sup>1</sup>Lipid Nanoparticle = "LNP"

<sup>2</sup>Emergency Use Authorization = "EUA"

<sup>3</sup>GSK adjuvant AS03 contains squalene, DL- $\alpha$ -tocopherol and polyborate

<sup>4</sup>Novavax adjuvant Matrix-M1 contains saporin extracted from the Quillaja saponaria Molina tree

<sup>5</sup>Measles-based vaccine, acquisition of Themis, collaboration with Institut Pasteur

<sup>6</sup>VSV = vesicular stomatitis virus; collaboration with IAVI = International AIDS Vaccine Initiative

## COVID-19 Vaccine Landscape

38

- **We expect more than one vaccine will be approved by FDA**
  - Different vaccines for different individuals
- **More than 150 vaccines in development**
  - Diversity of approaches is important since protective immunity is not yet understood
  - Technologies range from never tested before (mRNA) to 220 years old
  - Uncertainty exists around efficacy, durability and importantly, safety
- **Live attenuated vector systems in development include:**
  - Tonix (horsepox), Tonix (bovine parainfluenza), Merck (measles<sup>1</sup>- and VSV<sup>2</sup>-based), Zydus Cadila (measles-based)

<sup>1</sup>Measles-based vaccine, acquisition of Themis, collaboration with Institut Pasteur

<sup>2</sup>VSV = vesicular stomatitis virus; collaboration with IAVI = International AIDS Vaccine Initiative

© 2021 Tonix Pharmaceuticals Holding Corp.

## Live, Attenuated Virus Vaccines for Other Infectious Diseases<sup>1</sup>

39

- **Long term, durable immunity**
  - Expected to stimulate T cells and provide years to decades of protection
- **Single administration, scalable manufacturing**
  - Low dose is amplified by replication, mRNA and protein synthesis at vaccination site
- **Block forward transmission (infectivity)**
  - Key to conferring herd immunity and protecting immunocompromised

<sup>1</sup>For example, the eradication of smallpox, containment of measles, mumps, and rubella

© 2021 Tonix Pharmaceuticals Holding Corp.



## TNX-1800 Vaccination of Non-Human Primates Elicited Anti-SARS-CoV-2 Neutralizing Antibodies and Skin Reaction or “Take” in All Eight Animals

40

### STUDY DESIGN:

- Compares TNX-1800 (modified horsepox virus encoding CoV-2 spike protein) to TNX-801 (horsepox virus, live vaccine) at two doses in non-human primates. A control group received a placebo.
- Each of these five groups (TNX-1800 high and low dose; TNX-801 high and low dose and placebo) includes four animals.

### NEUTRALIZING ANTI-CoV-2 ANTIBODIES:

- At Day 14 after a single vaccination, all eight of the TNX-1800 vaccinated animals made anti-CoV-2 neutralizing antibodies ( $\geq 1:40$  titer).
- None of the eight TNX-801 vaccinated control animals, or any of the four animals in the placebo group, made anti-CoV-2 neutralizing antibodies ( $\leq 1:10$  titer).
- Level of neutralizing anti-CoV-2 antibody production was similar between the low and high dose TNX-1800 groups ( $1 \times 10^6$  Plaque Forming Units [PFU]) and  $3 \times 10^6$  PFU, respectively.

### SKIN TAKE BIOMARKER:

- All 16 animals vaccinated with either dose of TNX-1800 or the control TNX-801 manifested a “take”, or cutaneous response, signaling that the horsepox vector elicited a strong T cell immune response.

© 2021 Tonix Pharmaceuticals Holding Corp.



## TNX-1800 Vaccination of Non-Human Primates Findings, Conclusions and Next Phase

41

### TOLERABILITY:

- TNX-1800 and TNX-801 were well tolerated at both doses.

### DOSE:

- Supports the expectation that TNX-1800 at the low dose of  $1 \times 10^6$  PFU is an appropriate dose for a one-shot vaccine in humans.
- Indicates that 100 doses per vial is the target format for commercialization, which is suited to manufacturing and distribution at large scale.

### CONCLUSIONS:

- Data show that TNX-1800 induces a strong immune response to CoV-2 in non-human primates.
- Data confirm that “take” is a biomarker of a strong immunological response to TNX-1800’s vector, horsepox virus vaccine, and also indicate that “take” is predictive of a neutralizing antibody response to TNX-1800’s cargo COVID-19 antigen, which is the CoV-2 spike protein.

### NEXT PHASE:

- In the second phase of the study, the TNX-1800 vaccinated and control animals will be challenged with CoV-2. Results are expected in the first quarter of 2021.

© 2021 Tonix Pharmaceuticals Holding Corp.



## TNX-1800<sup>1</sup>: Engineered for Long-term Immunity

42

- **Based on “vaccinia” vaccine developed more than 200 years ago by Dr. Edward Jenner to prevent smallpox**
  - TNX-1800 has 99.7% colinear identity with circa 1860 smallpox vaccine<sup>2</sup>
  - Eradicated smallpox (only viral disease ever eradicated)
  - Elicits durable (many decades) T cell immunity
  - Single dose protection without adjuvants
  - Manufacturable at scale
  - Minimal “cold chain” supply issues
  - Glass-sparing packaging owing to small unit dose
- **Genetic analysis of early vaccines indicates that Tonix’s “horsepox” is closely related to Edward Jenner’s “vaccinia”**
  - Modern “vaccinia” evolved during the 220 years it was propagated by primitive methods – for over 120 years before “viruses” were identified

<sup>1</sup>TNX-1800 (horsepox/CoV-2 spike live vaccine) is at the pre-IND stage of development

<sup>2</sup>Brinkmann A et al, Genome Biology (2020) 21:286 <https://doi.org/10.1186/s13059-020-02202-0>

© 2021 Tonix Pharmaceuticals Holding Corp.

## Why Use a Horsepox Platform for a Vaccine?

43



### Horsepox can be engineered to express foreign genes

- Lack of persistence or genomic integration in the host
- Strong immunogenicity as a vaccine
- Readily manufacture at scale
- Live, attenuated vaccine – direct antigen presentation




### Potential advantages of horsepox over vaccinia

- Maintains strong immunogenicity with potentially improved tolerability
- Relative to non-replicating vaccinia, horsepox's replication in human cells provides direct antigen presentation, which is expected to trigger a T cell immune response, by Class I Major Histocompatibility Complex (MHC) Antigens
- Horsepox may behave differently than vaccinia as a vector, in part because of its different repertoire of genes that modulate immune responses and host range

© 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-1800 is Based on a Horsepox Virus (HPXV) Vector Designed to Express SARS-CoV-2 S Protein

44



\*TNX-1800 is at the pre-IND stage of development

© 2021 Tonix Pharmaceuticals Holding Corp.

## Vaccinia Induces a Skin Reaction Called "Take" – Described by Dr. Edward Jenner

45

**Vaccination by scarification!**

**Take**

- **Biomarker of protection**
  - Smallpox was eradicated using this marker
  - Revaccination indicated for recipients without "take"
- **Measure of T cell immunity**
  - No need for blood draws or complex laboratory studies
  - No other functional T cell assay is approved or in clinical use for vaccination


\*Example of major cutaneous reaction, or "take," resulting from a replication-competent live-virus vaccine delivered via scarification, indicating successful vaccination<sup>1,2</sup>

1. Fulginiti VA, et al. *Clin Infect Dis*. 2003;37(2):241-250.  
2. Liu L, et al. *Nature Med*. 2010;16(2):224-228.  
3. Centers for Disease Control and Prevention. Accessed April 15, 2020.  
<https://phl.cdc.gov/Details.aspx?pid=3276>

© 2021 Tonix Pharmaceuticals Holding Corp.

## Unique Challenges of SARS-CoV-2

46




1. Ciccardelli M, et al. *Eur Rev Adv Pharmacol Sci*. 2020;24:2763-2783.  
 2. Johnson AA, et al. *Jac (London in England)*. 2003;28(2):129-134.  
 3. White-Gentry A, et al. *Emerg Infect Dis*. 2005;11(7):1142-1145.  
 4. Centers for Disease Control and Prevention. Accessed November 2020. <https://www.cdc.gov/coronavirus/2019-nCoV/hcp/planning-scenarios.html>  
 5. Johns Hopkins University. Accessed November, 2020. <https://coronavirus.jhu.edu/map.html>

© 2021 Tonix Pharmaceuticals Holding Corp.

## Infection of Type II Pneumocytes Can Lead to Lethal Respiratory Illness

47




1. Knudsen L, et al. *Mitochondrion*. 2018;18(16):661-676.  
 2. Hogg JT, et al. *J Physiol Lung Cell Mol Physiol*. 2010;298(1):L1119-L120.  
 3. Xu Z, et al. *Lancet Respir Med*. 2020;8(4):420-422.  
 4. Lee WS, et al. *Nat Med*. 2020;16:1109-1115.

© 2021 Tonix Pharmaceuticals Holding Corp.

## SARS-CoV-2 Hijacks the Respiratory System to Spread Contagious Virus

48

- Virus factories release virions by continuous budding
- Breathing, speaking or coughing has the potential to release virions into the air and transmit infection to others



8a-Di 191, et al. *Cell*. 2020;9:1573-1585.


© 2021 Tonix Pharmaceuticals Holding Corp.



## CoV-2 Specific T Cells Kill the Virus Factories

49

- Natural immunity or vaccine protection has the potential to decrease forward transmission
- T cells specifically kill virally infected cells



Shi-Di Yi, et al. eLife. 2020;9:e57309.

© 2021 Tonix Pharmaceuticals Holding Corp.

## Contrasting T cell and Antibody Immunity

50

### • T cell immunity

- **Durable or long-lived (many years)**
- Recognize fragments of pathogens on the surfaces of infected cells
- Cannot recognize pathogens directly
- Potential to clear viral infections (by killing infected cells)
- Potential to block forward transmission (contagion) by infected people

### • Antibody immunity

- **Temporary or short-lived (typically 3-6 months)**
- Recognize pathogens directly
- Potential to block viral entry (by recognizing pathogens)
- Can only recognize virally infected cells that express viral surface proteins

© 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-1800 Upcoming Milestones

51

### Southern Research studies are addressing two key questions:

- 1 Completed: Vaccination of animals elicits an immune response to the S protein?
  - 4<sup>th</sup> Quarter 2020 - Non-human primate immune response positive results reported
- 2 Will immune response protect non-human primates against a challenge with SARS-CoV-2 virus?
  - 1<sup>st</sup> Quarter 2021 - Non-human primate results expected<sup>1</sup>

### Detailed analysis of primates planned, including:

- Major cutaneous reaction or "take" in primates
- In vitro stimulation of T cells
- Neutralizing antibodies

<sup>1</sup> We cannot predict whether the global COVID-19 pandemic will impact the timing of these milestones

© 2021 Tonix Pharmaceuticals Holding Corp.

## 2<sup>nd</sup> SARS-CoV-2 Vaccine Platform: Bovine Parainfluenza (BPI) Virus

52

### Collaboration with Kansas State University to develop a vaccine candidate for the prevention of COVID-19

- Utilizes a novel live attenuated vaccine vector platform and the CD40-ligand to stimulate T cell immunity
- TNX-2300<sup>1</sup> and TNX-2600<sup>1</sup> drive expression of CoV-2 spike and CD40-L

### Live attenuated vaccines based on bovine parainfluenza virus<sup>2-6</sup>

- Previously has been shown to be an effective antigen delivery vector in humans, notably well tolerated in infants and children
- Vector is well suited for mucosal immunization using a nasal atomizer, but it can also be delivered parenterally

### Data from small animals to measure efficacy in challenge studies using SARS-COV-2 are expected in the second quarter of 2021

<sup>1</sup>Pre-IND stage of development; <sup>2</sup>Halle, AA et al. *J Gen. Virology* (2003) 84:2153–2162; <sup>3</sup>Halle, AA et al. *J Virology* (2000) 74 (24): 11626–11635; <sup>4</sup>Karron RA et al. *J Inf Dis* (1995) 171: 1107–14; <sup>5</sup>Karron RA et al. *Vaccine* (2012) 30: 3975–3981; <sup>6</sup>Schmidt AC et al. *J Virology* (2001) 75(10): 4594–4603  
© 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-1300\* for the Treatment of Cocaine Intoxication

53

### Recombinant protein that degrades cocaine in the bloodstream<sup>1</sup>

- Double-mutant cocaine esterase (CocE)
- CocE was identified in a bacterium (*Rhodococcus*) that use cocaine as its sole source of carbon and nitrogen and that grow in soil surrounding coca plants<sup>2</sup>
- CocE catalyzes the breakdown of cocaine into metabolites ecgonine methyl ester and benzoic acid

### Phase 2 study completed by Reckitt Benckiser (TNX-1300 was formerly RBP-8000)<sup>3</sup>

- Volunteer cocaine abusers received cocaine 50 mg *i.v.* infusion over 10 minutes
- TNX-1300 given one minute after completion of cocaine infusion
  - Rapidly reversed the physiologic effects of cocaine; cocaine plasma exposures dropped by 90% within two minutes
  - Well tolerated with the most frequently reported adverse events being gastrointestinal disorders (including dry mouth, nausea); nervous systems disorders (including headache, dizziness) and skin and subcutaneous tissue disorders (including hyperhidrosis, dermatitis)

\*TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, *i.v.* solution) is an investigational new biologic and has not been approved for any indication.


<sup>1</sup> Gao D et al, *Mol Pharmacol*, 2009, 75(2):318-23.  
<sup>2</sup> Bresler MM et al, *Appl Environ Microbiol*, 2000, 66(3):904-8.  
<sup>3</sup> Nasser AF et al, *J Addict Dis*, 2014;33(4):289-302.

© 2021 Tonix Pharmaceuticals Holding Corp.

53

## TNX-1300 (Cocaine Esterase or CocE) Is a Fast-acting Cocaine Antidote

54



<sup>1</sup>Narasimhan D et al, *Future Med Chem*, 2012.

© 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-1300 Development Plan

55

- **Targeting to initiate a Phase 2 open-label, randomized pilot study of TNX-1300 in the first quarter of 2021**
- **Emergency department (ED) setting with patients coming in for treatment of cocaine and/or polysubstance intoxication**
- **Objectives**
  - Primary: To evaluate the safety of TNX-1300 in the ED setting
  - Secondary:
    - To evaluate TNX-1300 in the management of cardiovascular (CV) and other signs and symptoms associated with cocaine intoxication compared to usual care (UC) alone
    - To demonstrate reduction of plasma cocaine, cocaethylene, and ecgonine methyl ester levels after TNX-1300 administration and compare cocaine and cocaethylene levels of TNX-1300 group to those in UC alone

© 2021 Tonix Pharmaceuticals Holding Corp.

55

## TNX-1900 for the Treatment of Migraine and Craniofacial Pain – Overview

56

### **Novel intranasal oxytocin formulation being developed as a prophylactic treatment for chronic migraine**

- Based on a propriety formulation of oxytocin\*, a naturally occurring human hormone that acts as a neurotransmitter in the brain

### **Clinical and preliminary research has shown that low oxytocin levels in the body can lead to increase in headache frequency, and that increased oxytocin levels can relieve headaches**

- Certain other chronic pain conditions are also associated with decreased oxytocin levels

### **Oxytocin when delivered via the nasal route, results in enhanced binding of oxytocin to receptors on neurons in the trigeminal system, inhibiting transmission of pain signals**

### **Intranasal oxytocin has been shown in animals that it can also block CGRP release, a pathway known to be critical to the pathogenesis of migraine attacks.**

\*Oxytocin is approved by the U.S. Food and Drug Administration (FDA) as Pitocin®, an intravenous infusion or intramuscular injection drug, for use in pregnant women to induce labor. An intranasal form of oxytocin was marketed by Novartis to assist in nursing as Syntocinon®, but the product was withdrawn and the New Drug Application (NDA) has been discontinued.

© 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-1900 for the Treatment of Migraine – Prevalence

57

**One billion individuals worldwide suffer from migraines (~14% of population)<sup>1</sup>**

**Migraine is the second leading cause of years lived with disability<sup>1</sup>**

**In U.S., the estimated cost of all migraine headaches was \$78 billion in 2014<sup>2</sup>**

- Approximately 30% of those costs (\$23 billion) were direct medical costs

**Chronic migraine (≥ 15 headaches / month ) effects about 1-2% of individuals<sup>3</sup>**

- 75-150 million individuals worldwide
- 3-7 million in the U.S.

**CGRP antibodies are the only migraine specific prophylaxis drugs approved in decades**

- Requires parenteral administration (systemic effects on peripheral CGRP pathways)
- Long term safety concerns with prolonged systemic blockade of CGRP receptor<sup>4</sup>

<sup>1</sup> GBD 2016 Headache Collaborators, Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016, *Lancet Neurol* 2018; 17: 954-76

<sup>2</sup> Gooch, C. L., et al., The Burden of Neurological Disease in the United States: A Summary Report and Call to Action. *Ann Neurol*. 2017; 81:479-484

<sup>3</sup> Natoli et al., Global prevalence of chronic migraine: a systematic review, *Cephalgia*, 2010, 30:599-609

<sup>4</sup> Robbins, At Stake: The Possible Long-Term Side Effects of CGRP Antagonists, <https://www.practicepainmanagement.com/pain/headache/stake-possible-long-term-side-effects-cgrp-antagonists>, accessed November 8, 2020.

© 2021 Tonix Pharmaceuticals Holding Corp.

## TNX-1900 for the Treatment of Migraine – Mechanism of Action

58

**Preclinical research showed that nasally applied TNX-1900 selectively inhibits the activity of trigeminal pain-sensing nerve cells and blocks the release of CGRP**

- TNX-1900 is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP

**Migraine attacks are caused, in part, by the release of CGRP from pain-sensing nerve cells that are part of the trigeminal system**

- The CGRP binds to receptors on other nerve cells and starts a cascade of events that eventually results in a severe headache. This, in turn, reduces various kinds of trigeminal nerve associated pain and prevents CGRP from acting at receptors in the central nervous system that are involved in migraine.

**We believe targeted delivery of oxytocin could translate into selective blockade of CGRP release in the trigeminal ganglion and not throughout the body, which could be a potential safety advantage over systemic CGRP inhibition**

- In addition, daily dosing is more quickly reversible, in contrast to monthly or quarterly dosing, giving physicians and their patients greater control

© 2021 Tonix Pharmaceuticals Holding Corp.


## TNX-1900 for the Treatment of Migraine – Mechanism of Action (continued)

**CGRP: NEUROTRANSMITTER THAT HAS BEEN VALIDATED AS KEY MIGRAINE TARGET**

TNX-1900 believed to partially block release of CGRP in the trigeminal nerve

Proprietary Nasal to Brain Delivery

Permeates nasal mucosa  
Transported to trigeminal system and brain  
Oxytocin Receptors Co-Localize with CGRP in most Trigeminal Ganglia Neurons



Abbrev. CGRP, calcitonin gene-related peptide

## TNX-1900: Mechanism of Action (continued)

**In animal models, intranasal oxytocin concentrates in the trigeminal system**


Inhibits trigeminal neuronal firing, and decreases CGRP (and PACP) release onto meningeal vasculature and within the brainstem

- **Believed to have effects on:**

- Neurogenic inflammation
- Peripheral sensitization, where CGRP otherwise promotes neuronal-glia signaling of pain to trigeminal ganglion
- Central sensitization, in which CGRP otherwise causes sensitization of NMDA receptor, reducing threshold for glutamate – creating allodynia

- **Anti-CGRP antibodies may only work on inflammation and peripheral sensitization**

- Due to poor blood brain barrier penetration



Abbrev. CGRP, calcitonin gene-related peptide; PACP, pituitary adenylate cyclase-activating peptide  
Figure adapted from Krishnaswamy R et al. Anti-CGRP monoclonal antibodies: breakthrough in migraine therapeutics. Progress in Neurology and Psychiatry. Vol. 23.03, July-Sept, 2019.



## TNX-1900 for the Treatment of Migraine – Development Status

61

### In June 2020, Tonix acquired a proprietary formulation of nasal oxytocin solution for intranasal delivery from Trigemina

Also acquired migraine and pain treatment technologies of Trigemina, Inc. and assumed license for some of technologies from Stanford University

### A Phase 2 trial under an investigator-initiated IND has been completed in the U.S. using TNX-1900

Completed by Trigemina prior to acquisition

### Tonix intends to submit an IND application for this program to the FDA in the first quarter of 2021

### Targeting start of a Phase 2 study of TNX-1900 for the prophylactic treatment of chronic migraine in the U.S. in the second quarter of 2021

- Primary endpoint expected to be mean change in number of migraine headache days from the last 28 days of baseline to the last 28 days of treatment in each treatment group

© 2021 Tonix Pharmaceuticals Holding Corp.

## Pipeline<sup>1</sup> Summary – by Select Therapeutic Areas

62

Pain	Psychiatry	Addiction Medicine	Neurology
<ul style="list-style-type: none"> <li>• <b>TNX-102 SL (sublingual cyclobenzaprine) for fibromyalgia</b> Phase 3/RELIEF Phase 3/RALLY</li> <li>• <b>TNX-1900 (intranasal oxytocin) for craniofacial pain</b> Clinical – pre-IND stage</li> </ul>	<ul style="list-style-type: none"> <li>• <b>TNX-102 SL (sublingual cyclobenzaprine) for PTSD Sleep Disturbance</b> Phase 3/RECOVERY</li> <li>• <b>TNX-102 SL (sublingual cyclobenzaprine) for agitation in Alzheimer’s</b> Phase 2 ready FDA Fast Track designation</li> <li>• <b>TNX-601 CR (tianeptine oxalate and naloxone) for depression and PTSD</b> Clinical - Pre-IND stage</li> <li>• <b>TNX-1600 (triple reuptake inhibitor<sup>2</sup>) for PTSD, Depression and ADHD<sup>3</sup></b> Preclinical</li> </ul>	<ul style="list-style-type: none"> <li>• <b>TNX-1300 (cocaine esterase) for cocaine intoxication</b> Phase 2 FDA Breakthrough Therapy designation</li> <li>• <b>TNX-102 SL (sublingual cyclobenzaprine) for alcohol use disorder</b> Phase 2 ready</li> </ul>	<ul style="list-style-type: none"> <li>• <b>TNX-1900 (intranasal oxytocin) for migraine</b> Clinical – pre-IND stage</li> </ul>

<sup>1</sup> Experimental new medicines and biologics, not approved for any indication

<sup>2</sup> (2S,4R,5R)-5-(((2-amino-6-yl)thiazol-6-yl)methyl)amino)-2-(bis(4-fluorophenyl)methyl)tetrahydro-2H-pyran-4-ol) is an inhibitor of reuptake of three monoamine neurotransmitters (serotonin, norepinephrine and dopamine) – licensed from Wayne State University

<sup>3</sup> ADHD = attention deficit hyperactivity disorder

© 2021 Tonix Pharmaceuticals Holding Corp.

## Pipeline<sup>1</sup> Summary – by Select Therapeutic Areas (continued)

63

Public Health	Biodefense	Transplantation/ Autoimmunity	Oncology
<ul style="list-style-type: none"> <li>• <b>TNX-1800, TNX-1810, TNX-1820 &amp; TNX-1830 (live modified horsepox vaccine) for preventing COVID-19</b> Preclinical</li> <li>• <b>TNX-2300 and TNX-2600 (live bovine parainfluenza vaccine) for preventing COVID-19</b> Preclinical</li> </ul>	<ul style="list-style-type: none"> <li>• <b>TNX-801 (live horsepox vaccine) for preventing smallpox and monkeypox</b> Preclinical</li> <li>• <b>TNX-1200 (live vaccinia vaccine) for preventing smallpox and monkeypox</b> Preclinical</li> <li>• <b>TNX-701 (oral radioprotective agent) for radioprotection</b> Preclinical</li> </ul>	<ul style="list-style-type: none"> <li>• <b>TNX-1500 (anti-CD40-Ligand) for preventing rejection of solid organ transplants</b> Preclinical</li> <li>• <b>TNX-1500 (anti-CD40-Ligand) for treating autoimmune disease</b> Preclinical</li> </ul>	<ul style="list-style-type: none"> <li>• <b>TNX-1700 (rTFF2<sup>2</sup>) for treatment of gastric and pancreatic cancer</b> Preclinical</li> </ul>

<sup>1</sup> Experimental new medicines and biologics, not approved for any indication

<sup>2</sup> Recombinant Trefol Family Factor 2 – licensed from Columbia University

© 2021 Tonix Pharmaceuticals Holding Corp.

## Milestones – Recently Completed and Upcoming<sup>1</sup>

64

- ✓ September 2020 Interim analysis of TNX-102 SL Phase 3 F304/RELIEF study in fibromyalgia completed
- ✓ 4<sup>th</sup> Quarter 2020 Non-human primate immune response positive results reported
- ✓ 4<sup>th</sup> Quarter 2020 Positive topline data from TNX-102 SL Phase 3 F304/RELIEF study in fibromyalgia reported
- 2021 **Initiation of Phase 1 safety study of TNX-1800 for COVID-19 expected**
- 1<sup>st</sup> Quarter 2021 **Non-human primate efficacy data from TNX-1800 in COVID-19 models expected**
- 1<sup>st</sup> Quarter 2021 **Initiation of Phase 2 open-label safety study of TNX-1300 in ED setting for cocaine intoxication**
- 1<sup>st</sup> Quarter 2021 **Submission of IND application for TNX-1900 for the treatment of migraine**
- 2<sup>nd</sup> Quarter 2021 **Initiation of Phase 2 study of TNX-1900 for the treatment of migraine**
- 2<sup>nd</sup> Quarter 2021 **Small animal efficacy data from TNX-2300 in COVID-19 models expected**
- 2<sup>nd</sup> Quarter 2021 **Interim analysis of TNX-102 SL Phase 3 F306/RALLY study in fibromyalgia expected**
- 4<sup>th</sup> Quarter 2021 **Topline data from TNX-102 SL Phase 3 F306/RALLY study in fibromyalgia expected**

<sup>1</sup>We cannot predict whether the global COVID-19 pandemic will impact the timing of these milestones. © 2021 Tonix Pharmaceuticals Holding Corp.

## Management Team

65



**Seth Lederman, MD**  
President & CEO



**Gregory Sullivan, MD**  
Chief Medical Officer



**Bradley Saenger, CPA**  
Chief Financial Officer



**Jessica Morris**  
Chief Operating Officer



© 2021 Tonix Pharmaceuticals Holding Corp.



66



**Thank You!**

© 2021 Tonix Pharmaceuticals Holding Corp.

